Elevance Health, Inc. ELV
We take great care to ensure that the data presented and summarized in this overview for Elevance Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELV
View all-
Vanguard Group Inc Valley Forge, PA22.9MShares$6.74 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY20.7MShares$6.1 Billion0.26% of portfolio
-
State Street Corp Boston, MA10.6MShares$3.11 Billion0.16% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.14MShares$2.69 Billion0.49% of portfolio
-
Capital International Investors Los Angeles, CA6.49MShares$1.91 Billion0.45% of portfolio
-
Sanders Capital, LLC West Palm Beach, FL5.83MShares$1.72 Billion3.05% of portfolio
-
Wellington Management Group LLP Boston, MA5.79MShares$1.71 Billion0.5% of portfolio
-
Geode Capital Management, LLC Boston, MA5.09MShares$1.5 Billion0.14% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.35MShares$987 Million2.51% of portfolio
-
First Eagle Investment Management, LLC3.2MShares$943 Million2.52% of portfolio
Latest Institutional Activity in ELV
Top Purchases
Top Sells
About ELV
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Insider Transactions at ELV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 01
2025
|
Steven H Collis Director |
BUY
Grant, award, or other acquisition
|
Direct |
639
+50.0%
|
-
|
Jul 18
2025
|
Gail Boudreaux President and CEO |
BUY
Open market or private purchase
|
Direct |
8,500
+1.86%
|
$2,439,500
$287.05 P/Share
|
May 14
2025
|
Susan D. De Vore Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+20.7%
|
-
|
May 14
2025
|
Robert L Dixon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+5.5%
|
-
|
May 14
2025
|
Lewis Hay Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+4.96%
|
-
|
May 14
2025
|
Bahija Jallal Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+11.15%
|
-
|
May 14
2025
|
Antonio F Neri Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+10.88%
|
-
|
May 14
2025
|
Ramiro G Peru Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+6.04%
|
-
|
May 14
2025
|
Ryan M. Schneider Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+8.35%
|
-
|
May 14
2025
|
Deanna D Strable Soethout Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+26.75%
|
-
|
May 14
2025
|
R Kerry Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
601
+5.87%
|
-
|
Apr 24
2025
|
Mark Kaye EVP & CFO |
SELL
Open market or private sale
|
Direct |
4,588
-19.47%
|
$1,945,312
$424.82 P/Share
|
Mar 10
2025
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
443
-19.35%
|
$183,845
$415.13 P/Share
|
Mar 05
2025
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Open market or private sale
|
Direct |
3,504
-25.73%
|
$1,387,584
$396.3 P/Share
|
Mar 03
2025
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
6,531
+21.78%
|
-
|
Mar 03
2025
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
2,221
-23.86%
|
$877,295
$395.5 P/Share
|
Mar 03
2025
|
Ronald W Penczek CAO & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
706
+14.38%
|
-
|
Mar 03
2025
|
Ronald W Penczek CAO & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
198
-11.11%
|
$78,210
$395.5 P/Share
|
Mar 03
2025
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Grant, award, or other acquisition
|
Direct |
7,248
+10.76%
|
-
|
Mar 03
2025
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
2,613
-9.57%
|
$1,032,135
$395.5 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 65.4K shares |
---|---|
Open market or private purchase | 8.5K shares |
Payment of exercise price or tax liability | 24K shares |
---|---|
Open market or private sale | 16K shares |